Location of Repository

Gene expression-based screening for inhibitors of PDGFR signaling

By Alena A Antipova, Brent R Stockwell and Todd R Golub

Abstract

Inhibitors of the platelet derived growth factor receptor (PDGFR) signaling pathway are isolated using gene expression-based high-throughput screening (GE-HTS), a method that is applicable to other pathways

Topics: Method
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2397499
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (2006). A method for high-throughput gene expression signature analysis. Genome Biol
    2. (1998). A: Activation of phosphatidylinositol 3-kinase is necessary for differentiation of FDC-P1 cells following stimulation of type III receptor tyrosine kinases. Cell Growth Differ
    3. (2001). A: Activation of the insulin-like growth factor 1 signaling pathway by the antiapoptotic agents aurintricarboxylic acid and Evans blue. Endocrinology
    4. and BCRABL in cell cycle progression and leukemogenesis. Leukemia
    5. (2005). Antiproliferative plant and synthetic polyphenolics are specific inhibitors of vertebrate inositol-1,4,5-trisphosphate 3-kinases and inositol polyphosphate multikinase.
    6. (1990). Aszalos A: Aurin tricarboxylic acid, the anti-AIDS compound, prevents the binding of interferon-alpha to its receptor. Biochem Biophys Res Commun
    7. (1971). Aurintricarboxylic acid: inhibitor of initiation of protein synthesis.
    8. (1992). Ben-Sasson S: Reversal of basic fibroblast growth factor-mediated autocrine cell transformation by aromatic anionic compounds. Cancer Res
    9. (1996). Betsholtz C: PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell
    10. (2003). BR: Biological mechanism profiling using an annotated compound library. Chem Biol
    11. (2004). BR: Microarrays of small molecules embedded in biodegradable polymers for use in mammalian cell-based screens. Proc Natl Acad Sci USA
    12. (2008). Cellular assays in HTS.
    13. (1975). Competitive inhibition of Phe: tRNA ligase of sheep embryos by aurintricarboxylic acid.
    14. (2002). CR: Brain-derived neurotrophic factor induces longterm potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Arc synthesis.
    15. (1997). Destabilization, oligomerization and inhibition of the mitogenic activity of acidic fibroblast-growth factor by aurintricarboxylic acid.
    16. (1994). DG: Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell
    17. (1996). DG: The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci USA
    18. (2001). E: ERK induces p35, a neuron-specific activator of Cdk5, through induction of Egr1. Nat Cell Biol
    19. (1980). Eessalu TE: Sensitivity of progesterone receptors to aurintricarboxylic acid. Inhibition of nuclear uptake,
    20. Expression Omnibus [http://www.ncbi.nlm.nih.gov/geo/]
    21. (1980). G: Anti-inflammatory effect of aluminum or aurin tricarboxylic acid.
    22. (2006). Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell
    23. Inhibition of messenger ribonucleic acid attachment to ribosomes. II. Proposed mechanism for the design of novel antiviral agents.
    24. (1995). Inhibition of NAD(H)/NADP(H)-requiring enzymes by aurintricarboxylic acid. Toxicol Lett
    25. (1992). Isolation and structure elucidation of low molecular weight components of aurintricarboxylic acid (ATA).
    26. (1991). Isolation from commercial aurintricarboxylic acid of the most effective polymeric inhibitors of von Willebrand factor interaction with platelet glycoprotein Ib. Comparison with other polyanionic and polyaromatic polymers. Blood
    27. (1995). JA: Colony-stimulating factor 1-induced STAT1 and STAT3 activation is accompanied by phosphorylation of
    28. (1977). JG: Aurinetricarboxylic acid: a potent inhibitor of glucose-6-phosphate dehydrogenase. Chem Biol Interact
    29. (2004). JS: Aurintricarboxylic acid translocates across the plasma membrane, inhibits protein tyrosine phosphatase and prevents apoptosis in PC12 cells. Mol Cells
    30. (1982). Kinetic studies on inhibition of aminopropyltransferases by aurintricarboxylic acid in vitro. Chem Biol Interact
    31. (1995). KK: Aurintricarboxylic acid is an inhibitor of mu- and m-calpain. Biochem Mol Biol Int
    32. (1987). Lagunoff D: Phosphatidylcholine metabolism in endothelial cells: evidence for phospholipase A and a novel Ca2+-independent phospholipase C. Biochim Biophys Acta
    33. (2000). Meaningful relationships: the regulation of the Ras/ Raf/MEK/ERK pathway by protein interactions.
    34. (1995). Miyajima A: Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs.
    35. (1995). N-methyl-D-aspartate receptors activate transcription of c-fos and NGFI-A by distinct phospholipase A2-requiring intracellular signaling pathways. Mol Pharmacol
    36. (2001). Oncogenic kinase signalling. Nature
    37. (1994). Oncogenic Ras activates c-Jun via a separate pathway from the activation of extracellular signal-regulated kinases.
    38. (2006). Protein kinases as drug targets in cancer. Curr Cancer Drug Targets
    39. (2003). RA: PC12 cell activation by epidermal growth factor receptor: role of autophosphorylation sites.
    40. (2000). RJ: Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism.
    41. (1989). RR: Aurintricarboxylic acid is a potent inhibitor of phosphofructokinase.
    42. (1997). The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development
    43. (1999). TL: BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences.
    44. (2002). TR: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med
    45. (2006). TR: Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell
    46. (2004). TR: Gene expression-based high-throughput screening(GEHTS) and application to leukemia differentiation. Nat Genet
    47. (2007). TR: Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med
    48. (2002). TR: The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell
    49. (1997). Tyrosine phosphorylation of ErbB4 is stimulated by aurintricarboxylic acid in human neuroblastoma SH-SY5Y cells. Biochem Biophys Res Commun
    50. (1978). Weekes GA: Inhibition of hen oviduct estradiol receptor by aurintricarboxylic acid.
    51. (1999). Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev
    52. (1995). WJ: Excitotoxicity at both NMDA and non-NMDA glutamate receptors is antagonized by aurintricarboxylic acid: evidence for differing mechanisms of action.
    53. (2002). WW: Inhibition of cytokine-induced JAK-STAT signalling pathways by an endonuclease inhibitor aurintricarboxylic acid.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.